In patients with mutations that decrease GCase, the degradation of α-synuclein within the cell is impaired and lysosomal functioning is compromised, leading to increased levels of oligomeric α-synuclein, which results in dopaminergic neuronal death in PD. This evidence concerns the gene SNCA and Parkinson disease.